<DOC>
	<DOCNO>NCT02088541</DOCNO>
	<brief_summary>This randomize , multicenter , open-label , Phase 2 study SINE compound , Selinexor give orally versus specify investigator choice ( one three potential salvage therapy ) . Patients age ≥ 60 year relapsed/refractory AML type except AML M3 , one prior therapy , never undergone currently eligible stem cell transplantation currently deem unfit intensive chemotherapy .</brief_summary>
	<brief_title>Selinexor ( KPT-330 ) Older Patients With Relapsed AML</brief_title>
	<detailed_description>This randomize , multicenter , open-label phase 2 study SINE compound , Selinexor give orally versus restrict investigator choice ( i.e. , one three potential salvage therapy ) . Patients never transplant eligible , currently deem unfit intensive chemotherapy , ≥ 60 year old , AML ( except Acute Promyelocytic Leukemia : APL , AML M3 ) one prior treatment either hypomethylating agent regimen include Ara-C , meet inclusion exclusion criterion randomize receive either oral Selinexor physician 's choice ( one three potential treatment : best supportive care ( BSC ) alone , BSC + hypomethylating agent , BSC + low dose Ara-C disease progression , death intolerance occur .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Decitabine</mesh_term>
	<mesh_term>Azacitidine</mesh_term>
	<mesh_term>Hydroxyurea</mesh_term>
	<criteria>Age ≥ 60 year relapsed/refractory AML type except acute promyelocytic leukemia ( APL ; AML M3 ) , least 1 prior AML therapy , never undergone , currently eligible , stem cell transplantation , currently deem unfit intensive chemotherapy . ECOG ≤ 2 . Must available archival recently acquire bone marrow biopsy/aspiration tumor tissue central review eligible . Relapsed refractory AML , define either : recurrence disease complete remission ( CR ) , failure achieve CR initial therapy . Must receive least 1 prior line AML therapy give standard dos must progress recent therapy . Prior therapy must include : hypomethylating agent least 2 cycle . At least 2 week must elapse since last antileukemia treatment ( exception hydroxyurea ) first dose study . Treatment investigational agent within 3 week prior first dose study . Presence central nervous system ( CNS ) leukemia . In blast transformation chronic myeloid leukemia ( CML ) . Prior myelodysplastic syndrome ( MDS ) acceptable ; prior treatment MDS count AML therapy . Major surgery within 2 week first dose study drug . Patients must recover effect surgery perform great 2 week previously . Concurrent active malignancy treatment . Known active hepatitis B virus ( HBV ) C virus ( HCV ) infection ; know positive HCV ribonucleic acid ( RNA ) HBsAg ( HBV surface antigen ) . Known HIV infection . Unable swallow tablet , patient malabsorption syndrome , disease significantly affect gastrointestinal function . Patients whose AML classify favorable accord European LeukemiaNet ( ELN ) disease risk assessment .</criteria>
	<gender>All</gender>
	<minimum_age>60 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Relapsed/Refractory Acute Myeloid Leukemia</keyword>
	<keyword>Acute Myeloid Leukemia</keyword>
	<keyword>AML</keyword>
	<keyword>Karyopharm</keyword>
	<keyword>Selinexor</keyword>
	<keyword>KPT-330</keyword>
</DOC>